Cancer Studies Omit Age and Sex Data on Drug Conjugate Nausea
A secondary analysis of 202 clinical studies reveals that trials of antibody–drug conjugates universally fail to report nausea and vomiting ...
A secondary analysis of 202 clinical studies reveals that trials of antibody–drug conjugates universally fail to report nausea and vomiting ...
A case report describes collapsing focal segmental glomerulosclerosis and subsequent progression to dialysis-dependent kidney failure following combination therapy with pembrolizumab ...
A clinical case report documents a marked objective partial response to enfortumab vedotin and pembrolizumab in a patient with untreated ...
A retrospective pharmacovigilance study of 38,371 FAERS reports across 13 approved antibody–drug conjugates found that linker-payload platforms and target antigens ...
A large international trial shows that combining immunotherapy and a targeted drug before surgery reduces the risk of death by ...
A retrospective international analysis found male metastatic urothelial carcinoma patients survived longer on enfortumab vedotin than females, with higher NECTIN-4 ...
A single-patient case report documents delayed toxic epidermal necrolysis after six cycles of pembrolizumab and enfortumab vedotin for metastatic urothelial ...
A case report in a 54-year-old man found that multimodality imaging supported a likely right ventricular metastasis from sarcomatoid urethral ...
A rare but serious infusion accident has been documented for the first time in the medical literature. Urologists at University ...
A new review argues that antibody–drug conjugates act as immune modulators through immunogenic cell death, Fc-mediated effector functions and tumour ...
We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.
Bioengineer.org © Copyright 2023 All Rights Reserved.
Bioengineer.org © Copyright 2023 All Rights Reserved.